We are live on ! Find out more
PTIXW

Protagenic Therapeutics Warrant
PTIXW

Delisted

PTIXW was delisted on the 2nd of January, 2026.

Back to rankings

3 hedge funds and large institutions have $13K invested in Protagenic Therapeutics Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3 → 3 (0)

0.29% less ownership

Funds ownership: 2.06% → 1.77% (-0.29%)

75% less capital invested

Capital invested by funds: $53K → $13K (-$40K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$3.32K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$534
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$12K -$3.32K -42,726 -13%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$1K -$534 -6,879 -26%

PTIXW Hedge Fund Activity: Q3 2022 in Review

3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q3 2022, worth a combined $13K — down 75% from $53K a quarter earlier.

Fund positioning in PTIXW was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Warberg Asset Management, cutting an estimated $3.32K.

  • 3 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $13K of Protagenic Therapeutics Warrant stock for Q3 2022, down 75% quarter-over-quarter.
  • 0 funds opened new Protagenic Therapeutics Warrant positions in Q3 2022 and 0 closed out.
  • The largest Protagenic Therapeutics Warrant seller in Q3 2022 was Warberg Asset Management, an estimated $3.32K sold.

Based on aggregated 13F filings for Q3 2022.